8-K current report · filed Sep 24, 2026

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) 8-K Current Report: September 24, 2026

Item EX-99.1Item 5.02CLOV overview

Short answer

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on September 24, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 5.02 (Departure/Election of Directors or Officers). Two directors appointed September 22, 2026, filling vacancies and expanding the Board to nine members.

CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Two directors appointed September 22, 2026, filling vacancies and expanding the Board to nine members
  • Senator Torricelli joins the Audit Committee, adding healthcare and governance experience
  • Dr. Miller joins the Clinical Committee, bringing Medicare policy, regulation and health-plan expertise
  • Each receives a pro rata 2026 retainer and RSUs valued at $200,000, prorated through December 31, 2026
  • Appointments strengthen oversight amid healthcare regulatory and clinical governance demands

Item EX-99.1 · Exhibit EX-99.1

  • Former Senator Robert Torricelli and Dr. Brian J. Miller appointed directors, filling two vacancies
  • Board expanded to nine directors, strengthening governance capacity
  • Torricelli joins Audit Committee with federal healthcare policy and Clover subsidiary experience
  • Miller joins Clinical Committee, adding Medicare payment, regulatory, and practicing physician expertise
  • Appointments support Clover’s Medicare Advantage strategy but create no disclosed immediate financial impact

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings

Get the next CLOV 8-K as it lands

Follow CLOV for push alerts, or ask the research agent what this filing means.